



## AMP 2024 Committee and Subdivision Annual Reports

### Board of Directors

President	Maria E. Arcila, MD
President-Elect;	Jane S. Gibson, MS, PhD
Awards and Strategic Opportunities Committee Chair	
Past President and Nominating Committee Chair	Laura J. Tafe, MD
Secretary-Treasurer and Finance Committee Chair	Yasmine M.N. Akkari, PhD
Clinical Practice Committee Chair	Susan J. Hsiao, MD, PhD
Economic Affairs Committee Chair	Jay Patel, MD
International Affairs Committee	Rami Mahfouz, MD, MPH
Membership Affairs Committee Chair	Yaolin Zhou, MD
Professional Relations Committee Chair	Eric Konnick, MD, MS
Program Committee Chair	Jonathan Nowak, MD, PhD
Publication & Communication Committee Chair	Patricia Tsang, MD
Training & Education Committee Chair	Marjorie David, MD, MS
Genetics Subdivision Chair	Matthew Lebo, PhD
Hematopathology Subdivision Chair	Rena R. Xian, MD
Infectious Diseases Subdivision Chair	Kirsten St. George, MAppSc, PhD
Informatics Subdivision Chair	Annette Leon, PhD, MSc
Solid Tumors Subdivision Chair	Anthony N. Snow, MD
Early Career Member	Adam Fisch, MD, PhD
Early Career Member	Panieh Terraf, PhD
Patient Advocate	Andrea E. Ferris, MBA
Chief Executive Officer	Laurie S. Menser, CAE

## AMP Awards Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Jane S. Gibson, MS, PhD
Member	Margaret Gulley, MD
Member	Shelby Melton, MD
Member	Shi Yang, MD
Member	Anna Yemelyanova, MD
Member ( <i>Ex Officio</i> – President)	Maria E. Arcila, MD
Member ( <i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

### PURPOSE SUMMARY:

The Awards Committee consists of 5 members (4 appointed) who oversee the nomination and selection of the recipient of the Award for Excellence in Molecular Diagnostics, Jeffrey A. Kant Leadership Award, and, if determined applicable, the recipient(s) of the Meritorious Service Award(s). The Committee evaluates the current awards, addresses the need for new awards, and conducts the formal nomination process for potential award recipients.

The President-Elect serves as the Chair of the Awards Committee. The remaining 4 committee members are appointed by the Board for a two-year, renewable term, up to a maximum of six years. The annual selection of 2 incoming committee members is conducted by the committee and the candidates' names are brought forward for Board approval and appointment.

### Timeline for AMP Awards

The Awards Committee coordinated the timing of the AMP recognition awards as follows:

- Ongoing: Nominations from the Board, Committees, and Membership
- April: Review and selection by Awards Committee
- April through May: Notification of recipients
- May through September: Assess need for new recognition awards, if any

### Selected Award Recipients

- 2024 Jeffrey A. Kant Leadership Award: Ronald M. Przygodzki, MD
- 2024 Meritorious Service Award: Eric Q. Konnick, MD, MS, FCAP
- 2026 Award for Excellence in Molecular Diagnostics: To be announced in Spring 2026

## AMP Clinical Practice Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Susan Hsiao, MD, PhD
Genetics Subdivision Representative	Ann Moyer, MD, PhD
Genetics Subdivision Representative	Jennifer Laffin, PhD
Hematopathology Subdivision Representative	Pawel Mroz, MD, PhD
Hematopathology Subdivision Representative	Susan Harley, MD
Infectious Diseases Subdivision Representative	Erin Graf, PhD
Infectious Diseases Subdivision Representative	Meghan Starolis, PhD
Informatics Subdivision Representative	Weiwei Zhang, PhD
Informatics Subdivision Representative	Andrea Sboner, PhD
Solid Tumors Subdivision Representative	Katherine Geiersbach, MD
Solid Tumors Subdivision Representative	Lauren Ritterhouse, MD, PhD
Junior Member	Samuel Harvey, MD, PhD
Junior Member	Igor Odintsov, MD
Member ( <i>Ex Officio</i> – President)	Maria E. Arcila, MD
Member ( <i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

### PURPOSE SUMMARY:

The Clinical Practice Committee (CPC) is comprised of AMP members with expertise in one or more of the molecular specialties: infectious diseases, hematopathology, solid tumors, genetics, and informatics. Its purpose is to address the challenges of clinical laboratories and, therefore, improve the service we provide. The AMP Clinical Practice Guidelines Program is comprised of multiple AMP-led working groups that plan, organize, and coordinate efforts such as practice guidelines, sample exchanges, reporting surveys, validation and quality control measures, and advocate for policies that will advance the practice of high quality clinical molecular pathology services. The majority of these projects include representation from other professional organizations and groups. AMP's External Representatives Program additionally fosters collaboration by providing AMP subject matter experts to clinical practice projects led by other professional organizations and groups.

### Publications

- *DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium.* Published in the October 2024 issue of the *Journal of Molecular Diagnostics*. Karen Weck (Chair), Victoria Pratt (Co-Chair), Larisa Cavallari, Makenzie Fulmer, Andrea Gaedigk (PharmVar representative), Houda Hachad, Yuan Ji, Lisa Kalman, Reynold Ly, Ann Moyer (CAP representative), Stuart Scott, Amy Turner, Ron van Schaik (DPWG and ESPT representative), and Michelle Whirl-Carrillo (CPIC and PharmGKB representative). ACMG representative: Edward Esplin. DOI: <https://doi.org/10.1016/j.jmoldx.2024.05.015>.
- *Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer.* Published in the August 2024 issue of the *Journal of Molecular Diagnostics*. Larissa Furtado (Chair), Carlo Bifulco (SITC representative), Daniel Dolderer, Susan Hsiao, Benjamin Kipp, Neal Lindeman (CAP representative), Lauren Ritterhouse, Robyn Temple-Smolkin, Ahmet

Zehir, and Jonathan Nowak. ASCO representative: Solange Peters. DOI:

<https://doi.org/10.1016/j.jmoldx.2024.05.002>.

- *Slice Testing—Considerations from Ordering to Reporting: A Joint Report of the Association for Molecular Pathology, College of American Pathologists, and National Society of Genetic Counselors*. Published in the March 2024 issue of the *Journal of Molecular Diagnostics*. Rong Mao (Chair), Jeffrey SoRelle, Birgit Funke, Celeste Eno, Jianling Ji, Avni Santani (CAP representative), Pinar Bayrak-Toydemir, Megan Wachsmann, and Karen Wain (NSGC representative). DOI: <https://doi.org/10.1016/j.jmoldx.2023.11.008>.

### **Additional Accomplishments**

- Multiple CPC members hosted or presented AMP Webinars.
- Multiple AMP working group projects are underway.
- CPC members actively brainstormed new project ideas. Several of these project ideas are awaiting launch next year.
- Assisted AMP Advocacy and the various Subdivisions with input for their various initiatives where applicable.
- Multiple AMP Associate Members are working on CPC working groups as Junior Members.

### **Requests from the CPC**

- We encourage all AMP members to alert the Board or appropriate committees when laboratory guidelines or recommendations are opened for public comment.
- We encourage AMP members to actively contribute to calls for information from the CPC.
- Suggestions from AMP members for new CPC initiatives are always welcome! Visit <https://www.amp.org/clinical-practice/clinical-practice-overview/> for more details or email [ampclinicalpractice@amp.org](mailto:ampclinicalpractice@amp.org).

### **AMP Clinical Practice Guidelines Program**

<b>Working Group / Task Force</b>	<b>Members</b>
NGS Utility for Assessment of T/B-cell Clonality	David Viswanatha (Chair), Keyur Patel, Maria Arcila, Timothy Greiner, Joseph Khoury (CAP representative), David Wu, Devon Chabot-Richards (SH representative), and Habibe Kurt
Guidance/Standards for Tumor Mutational Burden Testing by Molecular Methods	Larissa Furtado (Chair), Jeffrey Gregg, Benjamin Kipp, Jonathan Nowak, Susan Hsiao, Antonia Sepulveda, Ahmet Zehir, Jeremy Segal, Lauren Ritterhouse, Carlo Bifulco (SITC representative), Neal Lindeman (CAP representative), Solange Peters (ASCO representative), and Daniel Dolderer
Molecular MRD Monitoring in Acute Myeloid Leukemia	Keyur Patel (Chair), Noah Brown, Marian Harris, Rashmi Goswami, Annette Kim, Rena Xian (CAP representative), David Wu (SH representative), Hong Fang, Nikhil Patkar, Dale Bixby, and Harrison Tsai
Clinical Whole Exome Sequencing for Inherited Conditions as a First Line Test: Spectrum of applications and standards	Rong Mao (Chair), Birgit Funke, Pinar Bayrak-Toydemir, Jianling Ji, Megan Wachsmann, Celeste Eno, Avni Santani (CAP representative), Karen Wain (NSGC representative), and Jeffrey SoRelle
Homologous recombination deficiency (HRD) assessment using next generation sequencing (NGS)	Susan Hsiao (Chair), Lawrence Jennings, Diana Mandelker, Vera Paulson, Michelle Shiller, Tracy Stockley, Eric Vail, Anna Yemelyanova, Destin Black (ACCC representative), Ian Hagemann (CAP representative),

	Praveen Vikas (ASCO representative), and Kelly Devereaux
CAP/ IASLC/AMP Molecular Testing Guideline for Selection of Lung Cancer Patients for <i>EGFR</i> and <i>ALK</i> Tyrosine Kinase Inhibitors – Revision	Neal Lindeman (AMP Co-Chair), Maria Arcila, David Kwiatkowski, Lynette Sholl, Laura Tafe, and Dhananjay Chitale
Validation of Next-Generation Sequencing Panels for Gene Fusion and Splice Variant Detection	Laura Tafe (Chair), Alanna Church (Co-Chair), Eduardo Castro-Echeverry, Marjorie David, Suneel Kamath (ASCO representative), Michael Kluk, Ravindra Kolhe (CAP representative), Christian Kunder, Andres Madrigal, Fatimah Nahhas, and Valentina Nardi
Update of “Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists”	Marilyn Li (Chair), Cindy Vnencak-Jones (Co-Chair), Amir Behdad, Ozge Ceyhan-Birsoy (ACMG representative), Catherine Cottrell, Eric Duncavage, Melissa Gildenberg, Obi Griffith (CGC representative), Annette Kim (SH representative), Shashikant Kulkarni (ClinGen Cancer Variant Interpretation representative), Christine Lovly (ASCO representative), Jason Rosenbaum, Somak Roy, Eytan Stein (ASH representative), Lea Surrey (CAP representative), Scott Turner, and Kai Wang
Oncologist-friendly Biomarker Reporting	Jane Gibson (Chair), Dana Altenburger (CAP representative), Noah Brown, Amy Clark (ASCO representative), Joshua Coleman, Hanadi El Achi (CAP representative), Rajyasree Emmadi (Ex-Officio), Meera Hameed, Jennifer Laudadio, Anthony Provenzano (ASCO representative), and Christopher Suci
Patient-friendly Biomarker Reporting	Rajyasree Emmadi (Chair), Allison Cushman-Vokoun, Jane Gibson, Julie Hirschhorn, Jennifer Morrissette, Irene Newsham, Sinchita Roy Chowdhuri, and Eric Vail
Standardization of Clinically Relevant Pharmacogenetic Alleles (PGx) <i>DPYD</i>	Karen Weck (Chair), Victoria Pratt (Co-Chair), Larisa Cavallari, Edward Esplin (ACMG representative), Makenzie Fulmer, Andrea Gaedigk (PharmVar representative), Houda Hachad, Yuan Ji, Lisa Kalman, Reynold Ly, Ann Moyer (CAP representative), Stuart Scott, Amy Turner, Ron van Schaik (DPWG and ESPT representative), and Michelle Whirl-Carrillo (CPIC and PharmGKB representative)
Standardization of Clinically Relevant Pharmacogenetic Alleles (PGx) Overview	Karen Weck (Chair), Victoria Pratt (Co-Chair), Makenzie Fulmer, Andrea Gaedigk (PharmVar representative), Houda Hachad, Yuan Ji (ACMG representative), Lisa Kalman, Reynold Ly, Ann Moyer (CAP representative), Stuart Scott, Amy Turner, Ron van Schaik (DPWG and ESPT representative), and Michelle Whirl-Carrillo (CPIC and PharmGKB representative)
ICC-WHO Classifications Hematopathology Subdivision Leadership Task Force	Eric Duncavage (Chair), Rena Xian (Co-Chair), Noah Brown, Valentina Nardi, Mark Ewalt, Amir Behdad, Pawel Mroz, Joanna Conant, and Jennifer Bynum
Clinical Validation of cfDNA and ctDNA Assays	Panieh Terraf (Chair), Christina Lockwood (Co-Chair), Navid Sadri, Rena Xian, Henning Stehr, Shamini Selvarajah, Pawel Mroz, Thuy Phung, Venkata

	Yellapantula, Christian Rolfo (ISLB representative), Mark Ewalt (CAP representative), and Samuel Harvey
--	---

### **AMP External Representatives Program**

<b>AMP Representative</b>	<b>Collaborating Organization(s)</b>	<b>Workgroup / Committee</b>
Ravindra Kolhe	American College of Medical Genetics and Genomics	Points to Consider for the Clinical Validation and Implementation of Optical Genome Mapping
Jianling Ji Matija Snuderl	American College of Medical Genetics and Genomics	Points to Consider for the Implementation of DNA Methylation Arrays for Clinical Diagnostics
Carolyn Sue Richards	American College of Medical Genetics and Genomics	Incidental Findings in Inherited Diseases Update Workgroup
Scott Turner	American College of Medical Genetics and Genomics, American Society of Human Genetics, Cancer Genomics Consortium, EMQN, HUGO	Technical Laboratory Standards for Interpretation and Reporting of Acquired Copy-number Abnormalities and Copy-neutral Loss of Heterozygosity in Neoplastic Disorder
Marilyn Li	American College of Medical Genetics and Genomics, ClinGen	Somatic Cancer Clinical Domain Workgroup
Julie Gastier-Foster Scott Topper	American College of Medical Genetics and Genomics, ClinGen, College of American Pathologists	Interpretation of Sequence Variants Update Workgroup
Shashirekha Shetty	American College of Medical Genetics and Genomics, ClinGen, College of American Pathologists	2020 ACMG/ClinGen Technical Standards for Interpretation and Reporting of Constitutional Copy Number Variants (CNVs) Workgroup
Somak Roy Fei Dong	American College of Medical Genetics and Genomics, College of American Pathologists, and HUGO Gene Nomenclature Committee with representation from EMQN and Association for Clinical Genomic Science	Technical Standards for the Reporting and Sharing of Interpreted Genomic Variation in Journals Workgroup
Rena Xian	American Society of Clinical Oncology	Cell-free DNA Testing Guideline Expert Panel
Dara Aisner	American Society of Clinical Oncology	Multi-Site Guideline Advisory Group
Sinchita Roy- Chowdhuri	American Society of Cytopathology	Organizational liaison
Eric Duncavage	Association of Community Cancer Centers	Advisory Committee
Dara Aisner Sinchita Roy- Chowdhuri	Association of Community Cancer Centers	Operational Pathways in Lung Cancer

Michelle Shiller	Association of Community Cancer Centers	Cancer Diagnostics Advisory Committee
Michael Dorschner	BLOODPAC	MRD Clinical Validation Working Group
Timothy O'Leary	BLOODPAC	MRD/Multi-Cancer Early Detection Recommended Data Elements Working Group
Aatur Singhi	BLOODPAC	Early Cancer Detection and Screening Working Group
Jacquelyn Reuther	BLOODPAC	bTMB Analytical Validation Working Group
Rina Kansal	BLOODPAC	CHIP Working Group
Bing Melody Zhang	BLOODPAC	Molecular Residual Disease (MRD) Analytical Validation Working Group
Richard Hickman	BLOODPAC	CSF Brain Tumor Workgroup
Christina Lockwood	BLOODPAC	Advisory Committee, Analytical Validation Workgroup, and Minimal Data Elements Workgroup
Sanja Dacic	Cancer Support Community	Lung Biomarker Digital Tool Advisory Board
Mehdi Nassiri	Centers for Disease Control and Prevention	Forum on Adoption of Standards for Laboratory Data Exchange and Interoperability
Daniel Jones	Clinical Laboratory Improvement Advisory Committee	Next Generation Sequencing Best Practices Forum
Somak Roy	Clinical Laboratory Standards Institute	Document Development Committee on Sequencing Bioinformatics for Human Genetics and Oncology (MM25) work group
Christina Lockwood	Clinical Laboratory Standards Institute	Document Development Committee on Liquid Biopsy Methods for Oncology (MM28) work group
Daniel Sabath	College of American Pathologists	Molecular Oncology Committee
Ryan Schmidt	College of American Pathologists	Genomic Medicine Resource Committee; Clinical Grade HGVS Workgroup
Betsy Bove	College of American Pathologists, American College of Medical Genetics and Genomics	Pharmacogenomics (PGx) Subcommittee of the Biochemical and Molecular Genetics Committee (BMGC) Workgroup
Mark Ewalt	College of American Pathologists, International Clinical Cytometry Society	Evaluation of Minimal Residual Disease in Acute Lymphoblastic Leukemia Guideline workgroup
Lauren Ritterhouse (Expert Panel) Ahmet Zehir	College of American Pathologists, American Society of Clinical Oncology	PD-L1 Testing of Patients with Lung Cancer for Selection of

		Immune Checkpoint Inhibitor Therapies Workgroup
Mehdi Nassiri	Food and Drug Administration	SHIELD Consortium - Standardization of Lab Data to Enhance Patient-Centered Outcomes Research and Value-Based Care
Maria Bettinotti	Foundation for the National Institutes of Health	Biomarkers Consortium Steering Committee for Inflammation and Immunity
Snehal Patel	Foundation for the National Institutes of Health	Biomarkers Consortium Steering Committee for Cancer
Jing Xu	Foundation for the National Institutes of Health	Steering Committee for Cancer: Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) work group
Rick Nolte	JMDI	Coronavirus Standards Working Group
Sinchita Roy-Chowdhuri	LUNGeVity	"How to Read Your Biomarker Testing Results Report" patient pamphlet
Mary Beth Beasley	LUNGeVity	Reflex testing in NSCLC Workgroup
Yaolin Zhou Joshua Deignan	Test Renaming for Understanding and Utilization (TRUU-Lab) coalition	Steering Committee
Valentina Nardi	Variant Interpretation for Cancer Consortium	Gene Fusion Oncogenicity Work Group
Panieh Terraf	Variant Interpretation for Cancer Consortium	Gene Fusion Curation Working Group
Emelia Calvaresi	National Institute of Standards and Technology	Genome in a Bottle Steering Committee
Antonia Sepulveda	World Health Organization International Agency for Research on Cancer	International Collaboration for Cancer Classification and Research (IC3R)



## AMP Economic Affairs Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Jay L. Patel, MD
Vice Chair, Coverage- Genetics and Oncology	Eric Vail, MD
Vice Chair, Coverage- Infectious Disease	Erin Graf, PhD
Vice Chair, New Codes & Pricing (Genetics Subdivision Rep.)	Victoria Pratt, PhD
Member	Nicholas Bevins, PhD
Member	Betsy Bove, PhD
Member	Jay Brock, PhD
Member	Maude Champagne, MBA
Member	Rajyasree Emmadi, MD
Member (Informatics Subdivision Rep.)	Jeffrey Gagan, MD, PhD
Member	Tanner Hagelstrom, PhD, MBA
Member (Solid Tumor Subdivision Rep.)	Susan Hsaio, MD, PhD
Member	Lloyd Hutchinson, MD
Member	Rina Kansal, MD
Member	Federico Monzon, MD
Member	Keyur Patel, MD, PhD
Member	Salvatore Priore, MD, PhD
Member	Navid Sadri, MD, PhD
Member	Jennifer Sanmann, PhD
Member	Michelle Schoonmaker, PhD
Member	Ester Stein, MBA
Member (Hemepath Subdivision Rep.)	Patricia Tsang, MD
Member	Heather Williams, MD
Member (Infectious Disease Subdivision Rep.)	Joseph Yao, MD
Junior Member	Jessica Williams, MD
Committee Advisor	Aaron D. Bossler, MD, PhD
Committee Advisor	Samuel K. Caughron, MD
Committee Advisor	Pranil Chandra, DO
Committee Advisor	Jan A. Nowak, MD, PhD
Member ( <i>Ex Officio</i> – President)	Maria E. Arcila, MD
Member ( <i>Ex Officio</i> – President-Elect)	Jane Gibson, PhD
Member ( <i>Ex Officio</i> – PRC Chair)	Eric Konnick, MD, MS
Member ( <i>Ex Officio</i> – Past President)	Laura Tafe, MD
Member ( <i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

### PURPOSE SUMMARY:

The Economic Affairs Committee (EAC) addresses, advises, and educates the AMP Board of Directors, membership, payors, legislators, and the public on economic issues of importance to the field of molecular pathology; prepares documents of importance to the Centers for Medicare & Medicaid Services (CMS); and develops and advocates for sound economic policies that promote the availability to patients of high-quality molecular pathology services. The Committee's scope encompasses short and long-term issues associated with the coding for molecular procedures, utilization of and coverage for molecular pathology, the determination of test pricing, and the potential economic impact of public policy decisions on molecular pathology practice. The Committee interacts with the American Medical Association and other interested organizations in order to achieve common goals.

## **2024 ACTIVITIES:**

The Centers for Medicare and Medicaid Services (CMS) have increasingly denied coverage and/or reduced payment for many medically necessary molecular pathology tests. These restrictions create a challenging environment for clinical practice and for innovators to translate new genomic discoveries into clinical applications. AMP employs government relations consultants, Jennifer Leib, Megan Anderson Brooks, and Lindsey Trischler of Innovation Policy Solutions, to advise the EAC on advocacy strategies and assist with fostering relationships between AMP, key federal agencies and Congressional offices. Additionally, the EAC is supported by AMP Associate Director of Public Policy and Advocacy, Annie Scrimenti, and AMP Senior Policy Analyst, Samantha Pettersen. AMP continues to work with the broader professional community to address policy challenges and opportunities to engage and inform payors who aim to achieve rightful reimbursements for appropriate patient care services.

## **Leadership**

In 2024, the Economic Affairs Committee leadership changes include the following:

**Jay Patel, MD**, Chair of the Economic Affairs Committee  
**Erin Graf, PhD**, Vice Chair, Coverage Infectious Diseases,  
**Eric Vail, MD**, Vice Chair, Coverage, Genetics & Oncology

## **AMP Molecular Pathology Economics Summit**

The 4th Annual AMP Economics Summit Occurred on August 16th, 2024 with the following objectives:

- Identify barriers to appropriate reimbursement for molecular pathology procedures;
- Examine the impact of these barriers on various stakeholders and patient access to care; and
- Propose potential solutions and/or novel approaches to overcoming barriers to implement shared policy goals from participating stakeholders in oncology, infectious diseases, and inherited conditions.

This year, a series of roundtable discussions focused on the impacts of Coding, Pricing, and Coverage has on various stakeholder groups including Clinical Laboratory Community, Patients and Providers, Manufacturers, and Pharmaceutical companies. Stakeholders explored unique challenges and barriers to patient access as well as potential solutions and/or novel approaches to overcoming these barriers, with the shared goal of identifying policy action items within each sector. Furthermore, AMP held in-depth breakout sessions that targeted coding, coverage and reimbursement issues and possible solutions. The last session outlined the largest threats to the economic landscape of molecular pathology. Overall, stakeholders committed to collaborate moving forward and the day concluded positively.

The 2024 Summit Planning Committee included: **Samuel Caughron, Jay Patel, Erin Graf, Victoria Pratt, Eric Vail, Jeff Gagan, Lloyd Hutchinson, Rina Kansal, Ester Stein, and Heather Williams**. The 2024 summit was incredibly successful and highly regarded by the participants. Due to this response, AMP intends to continue this on an annual basis.

## **Protecting Access to Medicare Act (PAMA)**

The Protecting Access to Medicare Act of 2014 (PAMA) required laboratories that perform clinical diagnostic laboratory tests to report the amounts they are paid by private insurers for said tests to the Centers for Medicare and Medicaid Services (CMS). CMS then set the Medicare payment rates for laboratory tests paid under the Clinical Laboratory Fee Schedule (CLFS) based on the weighted median of the private payor data. Since 2014, AMP has continued to express significant concerns to CMS and Congress on various occasions about issues with the first PAMA exercise and how rates were established (e.g., data entity and reporting entities).

In early 2020, the Laboratory Access for Beneficiaries (LAB) Act was passed by Congress. The LAB Act was supported by AMP and addressed some of AMP's and other stakeholders' concerns with PAMA. It delayed the next round of data reporting until 2021 and delayed the timing for payment reductions under PAMA.

Additionally, the LAB Act authorizes Medicare Payment Advisory Committee (MedPAC) to study the methodology CMS used to rate-set through PAMA.

Since the passage of the LAB Act, three additional pieces of legislation were passed: the CARES Act (to address the COVID-19 public health crisis) included an additional one-year delay to PAMA and the Protecting Medicare and American Farmers from Sequester Cuts Act, which was passed in December 2021, also included an additional one-year delay to PAMA. The Consolidated Appropriations Act of 2023 was passed in December 2022. This revised the phase-in of payment reductions under the Medicare private payor rate-based CLFS. Statutory phase-in of payment reductions is extended through calendar year (CY) 2026. This created a 0.0 percent reduction for CY 2023 and determined that payment may not be reduced by more than 15 percent for CYs 2024 through 2026. On September 25<sup>th</sup>, 2024 a continuing resolution passed that included another one year delay in PAMA cuts and reporting. Following these actions, the next PAMA reporting cycle will begin in 2026.

In April, AMP staff met with Majority and Minority Staff from the U.S House of Representatives Ways and Means Committee as well as the U.S. Senate Finance Committee Staff to discuss the possible passage of SALSA.

#### **Clinical Lab Fee Schedule for Calendar Year 2024**

During the summer, AMP provided written and oral comments to CMS on the Calendar Year (CY) 2025 Clinical Lab Fee Schedule (CLFS). **Dr. Victoria Pratt** represented AMP at the annual CLFS meeting on June 25, 2024. She presented crosswalk recommendations for the new and reconsidered CY2024 CLFS molecular pathology, genomic sequencing, and microbiology procedures.

Additionally, the Advisory Panel on Clinical Laboratory Diagnostic Tests (CDLTs), reviewed stakeholder recommendations presented to CMS in July and voted on the best approach to pricing new and reconsidered codes. The Panel was established by the Protecting Access to Medicare Act (PAMA) and advises CMS on various issues under PAMA including payment rates for new tests, including whether to use the crosswalk or gapfill methodology for initial price determination. Several AMP members are members of The Panel, with **Drs. Aaron Bossler**, and **Pranil Chandra** nominated by AMP to serve.

In late September, CMS released the CY2025 CLFS Preliminary Determinations for the new and reconsidered services. While a majority of the preliminary CMS determinations align with AMP and other laboratory organizations' recommendations, the a select few of the preliminary recommendations provided by CMS vastly differ from both the Advisory Panel and AMP recommendations, along with stakeholder input and, in many cases, do not represent the best options for crosswalks. Pricing determinations will be finalized later this year.

#### **Medicare and Private Payer Coverage Policies**

Monitoring emerging policies continued to be a major focus of the Coverage subcommittee led by **Dr. Erin Graf and Dr. Eric Vail**. AMP continues to advocate with CMS regarding coverage policy actions taken by Medicare Administrative Contractors (MACs). As of October 10, 2024, AMP has provided responses to various MACs for approximately seven draft local coverage determinations (dLCDs). AMP and the College of American Pathologists (CAP) frequently collaborate and draft joint responses. The EAC is very thankful to the AMP members that have volunteered their time and subject matter expertise to assist in responding to the diverse coverage policy issues. Additionally, earlier in 2024, AMP responded to one private payer coverage policy: Blue Cross Blue Shield (BCBS) Alabama Multitarget PCR Testing for the diagnosis of Bacterial Vaginosis. AMP is currently working on responses to BCBS California and Aetna.

#### **CPT Codes**

The EAC New Codes and Pricing Subcommittee, led by **Dr. Victoria Pratt**, advises and reviews new CPT code applications submitted to the Pathology Coding Caucus (PCC) and the Molecular Pathology Advisory Group (MPAG). In January 2024, **Dr. Samuel Caughron** accepted the position of advisor on the PCC. Throughout the year, the Subcommittee may submit new CPT code change proposals to AMA based on member need and input. The subcommittee also provided input to CMS' National Correct Coding Initiative (NCCI) to help ensure national

correct coding methodologies of procedure to procedure (PTP) and medically unlikely edits (MUEs) for molecular procedures and is working with a broad group of stakeholders to address issues with updates to the NCCI manual.

#### **Outside Organization Involvement**

- **Dr. Aaron Bossler** serves on the CPT Editorial Panel
- **Drs. Victoria Pratt, Joseph Yao, Aaron Bossler** serve on the AMA Proprietary Laboratory Analyses Technical Advisory Group (PLA-TAG)
- **Dr. Samuel Caughron** serves on the PCC, with **Dr. Keyur Patel** serving as the technical advisor.
- The AMA Molecular Pathology Advisory Group (MPAG) includes AMP members **Drs. Aaron Bossler, Ann Moyer, Madhuri Hegde, Jeremy Segal, Larry Jennings, and Victoria Pratt.**

## AMP Finance Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Yasmine Akkari, PhD
President	Maria E. Arcila, MD
President-Elect	Jane Gibson, PhD
Past President	Laura J. Tafe, MD
Member	Steven A. Schichman, MD, PhD
Member	Xiao-Ming Yin, MD, PhD
Chief Executive Officer	Laurie S. Menser, CAE

The Finance Committee oversees AMP's financial affairs, including reviewing revenue & expense reports and recommending to the Board for approval an annual operating budget and the investment policy for the Association's assets.

## AMP International Affairs Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair and Membership Affairs Liaison (Middle East)	Rami Mahfouz, MD
Member (Southeast Asia)	Kenneth Chang, MBCHB
Member (Latin America)	Renata A. Coudry, MD, PhD
Member and Italy Affiliate Coordinator	Francesco Curcio, MD
Member (South Asia)	Bibhu R. Das, PhD
Member and Korea Affiliate Liaison (East Asia)	Jieun Kim, MD, PhD
Member (Europe)	Fernando Lopez-Rios, MD
Member and India Affiliate Liaison (South Asia)	Deepak Mishra, MD
Member (South Asia)	Nikhil Patkar, MD
Member and German Affiliate Coordinator	Nicole Pfarr
Member and Training & Educ Liaison (Latin America)	Roberta Sitnik, PhD
Advisor	Helen Fernandes, PhD
Advisor	Jin-Yeong Han, MD, PhD
Member ( <i>Ex Officio</i> – President)	Maria E. Arcila, MD
Member ( <i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

### PURPOSE SUMMARY:

The International Affairs Committee (IAC):

- Enhances AMP as an international organization
- Promotes AMP's vision and mission internationally
- Facilitates international presence and participation in AMP groups and programs including AMP Europe and AMP Global
- Expands excellence in education and advocacy on behalf of patients, clinicians, and lab professionals to an international audience
- Enables the interaction of scientists and molecular pathologists in the various parts of the world
- Enhances AMP's international membership.

### 2024 ACTIVITIES:

- Approved and welcomed AMP's 9<sup>th</sup> International Affiliate member: Asociacion Iberoamericana de Patologia Molecular (AIPM)
- Selected new South Asian and European IAC Members
- Welcomed new MPAl and SIPMeT Coordinators on the committee
- AMP 2024 Annual Meeting Events:
  - Designed and released survey to collect data on the topic of Pharmacogenomics in the Era of Precision Medicine
    - This data was presented at the International Affairs Global Networking Lunch on Thursday and will be the focus of a companion webinar to be held in January or February 2025.
- Selected International Trainee Travel Awardees from Türkiye, Nigeria, and India.
- Awarded International Membership Grants to molecular professionals from India, Rwanda, and Syria.
- IAC Committee represented by its Chair assisted in the planning, organization, and launching of the AMP Europe 2024 in Madrid, Spain.
- Selected:
  - AMP Europe 2024 Young Investigator Travel Award and AMP Europe 2024 IMPACT recipients
- Supported AMP speakers at international (non-U.S.) conferences:
  - Supported speakers for AIPM's sponsored session at the IAP Mexico conference and approved speaker support for the 11<sup>th</sup> Congress of the Molecular Pathology Association of India.

## AMP Membership Affairs Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Yaolin Zhou, MD
Member	Barbara Anderson, MS
Member	Tejus Bale, MD, PhD
Member, Representative to Training & Education	Yang Cao, PhD
Member	Timothy Daniels, BS
Member	Kevin E. Fisher, MD, PhD
Member	Lisa Lansdon, PhD
Member	Mariana Macedo, MD, PhD
Member	Jennifer Morrissette, PhD
Member	Bijal Parikh, MD, PhD
Member	Jacquelyn Reuther, PhD
Member	Sherin Shaaban, MD, PhD
Member	Jessica Thomas, MD
Member	Ying Wang, PhD
Member	Shi Yang, MD
Junior Member	Eitan Halper-Stromberg, MD
Junior Member	Rand Abou Shaar, MD
International Affairs Liaison	Rami Mahfouz, MD
Member ( <i>Ex Officio</i> – President)	Maria E. Arcila, MD
Member ( <i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

### PURPOSE SUMMARY:

The AMP Membership Affairs Committee (MAC) provides recommendations to the Board and assistance to other committees regarding matters of membership and professional development. The committee plays an important role in helping AMP respond to the needs of its members and in facilitating the development of leaders in the field of molecular pathology.

### Ongoing Responsibilities:

- Assesses and makes recommendations that will enhance the professional development of AMP members and the benefits of AMP membership
- Provides regular and timely notification to members about opportunities for special projects within or outside of standing committees and subdivisions
- Facilitates leadership development for AMP through various initiatives such as the ad hoc and junior member volunteer process
- Receives requests from Chairs or Board for ad hoc members to work on projects and manages the volunteer application process
- Surveys member volunteers annually regarding their volunteer service experiences
- Surveys the membership periodically regarding how well their membership in AMP meets their needs and how well AMP is serving the needs of the profession
- Surveys non-members to help identify barriers to membership in AMP
- Conducts a member recruitment and retention program

### 2023-2024 Accomplishments

- Selected:
  - Three recipients for the AMP 2024 Technologist Travel Awards.
  - The recipient of the AMP 2024 Underrepresented in Medicine Travel Award.

- Planned and hosted:
  - 2024 AMP Annual Meeting First Timer’s Lunch with a focus on understanding the needs of first-time attendees (in addition to providing information about AMP and the AMP Annual Meeting)
  - Networking Session: How to Get Involved with AMP at the AMP 2024 Annual Meeting. Invited representatives from several committees to attend and share about their committee responsibilities and how to become more involved; obtained corporate sponsorship to cover the cost of snacks for this networking session.
- Redesigned the 2024 Membership Satisfaction Surveys (for AMP Regular members, Associate members, Technologist members, and non-members for each of the three categories) based on survey-design best practices (Yaolin Zhou, Bijal Parikh, Jennifer Morrisette, Tejus Bale, Kevin Fisher, Rami Mahfouz, Jacqueline Reuther, Eitan Halper-Stromberg, Yang Cao, Lisa Lansdon, and Ying Wang)
- Developed committee member-driven projects to increase recruitment, retention, and member satisfaction. These projects include:
  - Followed up with 106 first-time lunch attendees from 2023 Annual Meeting (Yaolin Zhou, Kevin Fisher, Shi Yang, Bijal Parikh, Jessica Thomas, Tejus Bale, Yang Cao, Rand Abou Shaar, Jacqueline Reuther, Lisa Lansdon, Barbara Anderson, and Tim Daniels) **(Complete)**
  - Created a “Vancouver at-a-Glance” cheat sheet for first time meeting attendees (Jennifer Morrisette, Eitan Halper-Stromberg, and Lisa Lansdon) **(Complete)**
  - Designed and distributed AMP First Timer’s Lunch pens (Yaolin Zhou) **(Complete)**
  - Worked with the Program Committee to enhance technologist specific content at the Annual Meeting (Barbara Anderson) **(Complete)**
  - Enhanced networking events at the Annual Meeting, including the Networking Session (Shi Yang & Jennifer Morrisette, with entire committee input) **(Complete)**
  - Fostering membership opportunities for trainees in low-income countries (Tejus Bale and Marina Macedo) **(Ongoing)**
  - Creating a comprehensive suite of projects to inform and recruit trainees as part of the new free Associate Membership program (Kevin Fisher, Eitan Halper-Stromberg, and Jessica Thomas) **(Ongoing)**
  - Expanding AMP’s micro-volunteer program so that everyone who wants to share their time and expertise with AMP has an opportunity to do so. (Lisa Lansdon) **(Ongoing)**
  - Co-Chaired the Training & Early Career Leadership Development Task Force (Eitan Halper-Stromberg) **(Complete)**
  - Creating an AMP Ambassador Pilot Program to inform and recruit trainees by word of mouth from fellow trainees. (Rand Abou Shaar) **(Ongoing)**
  - Continuing the Member Spotlights project. (Jacqueline Reuther, Bijal Parikh, Yang Cao, Kevin Fisher, and Marina Macedo) **(Ongoing)**
- Work closely with the International Affairs and Training & Education Committees to ensure that membership needs are met around the globe and through educational offerings. **(Ongoing)**

### **Diversity, Equity, and Inclusion (DEI) Working Group Activities**

- Member outreach: Members report increased confidence year-over-year in AMP’s efforts to support DEI.
- Member engagement: Developed a four-part series that focuses on real-life stories of molecular laboratory professionals with highly diverse backgrounds. Presenters discuss how their experiences are helping to promote the education, training, and practice of molecular pathology in communities of non-US background.
- Projects: Convened a project group to identify the current challenges of genomic test reporting for transgender individuals and suggest possible solutions for improvement.



## AMP Nominating Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Laura J. Tafe, MD
Genetics Subdivision Representative	Tina Hambuch Hawks, PhD
Genetics Subdivision Representative	Jane Houldsworth, PhD
Hematopathology Subdivision Representative	Mark D. Ewalt, MD
Hematopathology Subdivision Representative	Valentina Nardi, MD
Infectious Diseases Subdivision Representative	Ana María Cárdenas, PhD
Infectious Diseases Subdivision Representative	Morgan A. Pence, PhD
Informatics Subdivision Representative	Ahmet Zehir, PhD
Informatics Subdivision Representative	Jing Xu, MD, PhD
Solid Tumors Subdivision Representative	Nikoletta Sidiropoulos, MD
Solid Tumors Subdivision Representative	Jaclyn F. Hechtman, MD
Member ( <i>Ex Officio</i> – President)	Maria E. Arcila, MD
Member ( <i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

### PURPOSE SUMMARY:

The AMP Nominating Committee is composed of the Past President (Chair) and two representatives from each subdivision. The chair and subdivision representatives are responsible for recruiting qualified AMP members to run for elected offices. A ballot is compiled and made available for voting by all current Regular AMP members. Voting for elected offices takes place during the month of May or June each year.

### 2024 ACTIVITIES:

The Nominating Committee nominated Officers and Committee Representatives for the 2024 annual elections.

## AMP Professional Relations Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Eric Q. Konnick, MD
Vice Chair	Karen Weck, MD
Member	Esther Babady Otete, PhD
Member (Infectious Disease Subdivision Rep.)	Heather Blakenship, PhD
Member	David Bosler, MD
Member (AMP Rep. to FASEB Science Policy Committee)	Emilia Calvaresi, MD, PhD
Member (Hemepath Subdivision Rep.)	Betty Chung, DO, MPH, MA
Member (Solid Tumors Subdivision Rep.)	Jennifer Dien Bard, PhD
Member (Genetics Subdivision Rep.)	Xiaoli Du, PhD
Member	Andrea Ferreira-Gonzalez, PhD
Member	Bryan Iorgulescu, MD
Member	Thủy Phùng, MD, PhD
Member (Informatics Subdivision Rep.)	Jason Rosenbaum, MD
Member	Dan Sabath, MD, PhD
Member	Ryan Schmidt, MD, PhD
Member	Elizabeth Spiteri, PhD
Member	Andria Del Tredici, PhD
Member	Thao Truong, PhD, D(ABMM), M(ASCP)CM
Member	Oana Vele, MD
Member	Yaolin Zhou, MD
Junior Member	Pamela Robertson, PhD
Junior Member	Rosalie Sterner, MD, PhD
Committee Advisor	Roger Klein, MD, JD
Committee Advisor	Jordan Laser, MD
Committee Advisor	Jill Murrell, PhD
Member ( <i>Ex officio</i> – President)	Maria Arcila, MD
Member ( <i>Ex officio</i> – President-Elect)	Jane Gibson, PhD
Member ( <i>Ex officio</i> – Past President)	Laura Tafe, MD
Member ( <i>Ex officio</i> – EAC Chair)	Jay Patel, MD, MBA
Member ( <i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

### PURPOSE SUMMARY:

The AMP Professional Relations Committee (PRC) is the primary liaison between AMP and other organizations for public policy issues other than reimbursement, which is the purview of the Economic Affairs Committee.

Major responsibilities of the Committee include:

1. Communicating and coordinating activities with the appropriate government offices, coalitions, trade associations, and patient and professional organizations to inform policy discussions that have an impact on the practice of molecular pathology;
2. Developing AMP positions on emerging policy issues affecting molecular pathology;
3. Interacting with a wide variety of entities, including other professional associations, Congress and U.S. Federal Agencies such as CMS, FDA, CDC, DHHS;
4. Advocating for policy changes in legislation and regulation that will advance the practice of molecular pathology.

The committee membership includes individuals employed in a variety of medical, scientific, institutional and commercial capacities.

## **2024 ACTIVITIES:**

The PRC continues to monitor the activities of, and in some cases work with, federal agencies such as FDA and CMS as well as policy committees such as the Roundtable on Genomics and Precision Health at the National Academies of Sciences, Engineering, and Medicine. After extensive discussion, the committee drafts AMP's policy positions and comments to federal agencies and members of Congress. AMP's government relations consultants, Jennifer Leib, Megan Anderson Brooks, and Lindsey Trischler of Innovation Policy Solutions, LLC (IPS), inform the Committee of all policy and legislative activity, assist in drafting policy positions, provide advice regarding advocacy strategies, and guide AMP's presence on Capitol Hill. IPS along with AMP Associate Director of Public Policy and Advocacy, Annie Scrimenti and AMP Senior Policy Analyst, Samantha Pettersen, and when possible, Committee or other AMP members meet with congressional staff to educate them about issues relevant to molecular pathology, to offer AMP's expertise, and to advocate for AMP members' interests. (Note: As a 501c3 tax-exempt organization, AMP is prohibited from participating in any partisan activities and may not have a Political Action Committee (PAC). In addition, its direct and grassroots lobbying activities are limited per IRC 501h.)

### **FDA Initiates Rulemaking to Regulate Laboratory Developed Testing Procedures (LDPs) as Medical Devices, AMP fights back with legal action**

AMP has historically advocated for LDPs to be overseen by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments, 1988 (CLIA). However, the U.S. Food and Drug Administration (FDA) has overreached authority and finalized a rule on May 6, 2024 that would regulate LDPs as medical device. Prior to the finalization, AMP met with the White House and numerous Congressional offices to deter the administration from moving forward with the rule. .

Following this, AMP held a webinar on May 9<sup>th</sup> to discuss a preliminary analysis of the FDA's Final Rule. This event was highly attended reaching the cap of 1000 attendees, and 1300 registrants. A copy of the session was sent to all registrants.

AMP's efforts to halt the implementation of the final rule through Congressional channels are ongoing. AMP successfully attained inclusion of legislative language in the House Appropriations (government funding) bill for Fiscal Year (FY) 2025. The bill report language instructs the FDA to halt the implementation of the final rule and instead allow congress to work on a solution. In June, it was incorporated in the Committee markups and will be revisited most likely in December 2024. Additionally, AMP is working with Senate offices that seek to provide alternative legislative pathways to LDP regulation.

The severity of regulatory impositions the FDA seeks to pursue with the final rule would decimate the laboratory community at large and threaten the field of molecular pathology. Given this, AMP is taking legal action against the agency, citing the lack of statutory authority, as well as FDA's encroachment on the practice of medicine. This litigation does not halt the implementation of the rule. AMP submitted Opening briefs on September 27<sup>th</sup> to the Department of Justice (DOJ). The FDA and DOJ submitted rebuttal briefs, and AMP will respond to these arguments next week. All documents will be filed by December 23, 2024. Hearings will be held in Dallas, Texas, most likely in the Spring of 2025.

## **CLIA Modernization**

AMP maintains the position that Laboratory Developed testing Procedures (LDPs) should remain under the authority of the Centers for Medicare and Medicaid Services (CMS), Clinical Laboratory Improvement Amendments (CLIA).

Last year, the Regulatory Reform Task Force finalized a new CLIA Modernization Proposal to make changes to the current statute to reflect modern Molecular Pathology practices. The proposal definitively removes FDA oversight of LDPs and does not include a risk classification system, but instead focuses on enhancing transparency and clarifying ambiguities in current regulation, i.e. defining performance characteristics, clinical and analytical validity, and enhances the proficiency testing program to ensure testing quality without the need for a premarket review process. In light of the FDA final rule, AMP is dedicated to working with stakeholders and Congressional offices that continue to move this initiative forward to preserve a flexible system that fosters innovation as the most streamlined, cost-effective approach

In December of 2023 and continuing into 2024 AMP met with numerous congressional offices to educate them on the benefits of CLIA modernization. Notably, AMP received interest from Rep. Debbie Wasserman-Schultz (D-FL) and Dr. Neal Dunn (R-FL) as potential sponsors of the bill. AMP met with nearly 40 Congressional offices to discuss the CLIA modernization proposal.

## **Gene Patent Law**

In 2024, AMP strongly advocated against The Patent Eligibility and Restoration Act, 2023 (S. 2140) which is an attempt to permit patents of genes, laws of nature and abstract ideas. This bill was introduced by Senator Coons (D-DE) and Tom Tillis (R-NC) and would revise Section 101 of the Patent Act, which defines patent eligibility. the reversal of the Supreme Court decision, *AMP v. Myriad*. AMP submitted Testimony to the Senate Committee on the Judiciary, Subcommittee on Intellectual Property Hearing on “the Patent Eligibility Restoration Act- Restoring Clarity, Certainty, and Predictability to the U.S Patent System” noting that the innovation of molecular diagnostics is directly due to *AMP v. Myriad*. AMP also circulated a letter signed by over 90 stakeholders Opposing PERA. Of note, on September 6<sup>th</sup>, the bill was also introduced in the House by Representatives Kiley and Peters. On the Senate side, the bill’s progression through the IP Subcommittee markup included a Manager’s Amendment, put forward by Sen. Tillis. This states that PERA would rescind the *AMP v. Myriad* case, along with two other unanimously decided Supreme Court cases (*Alice Corp v. CLS Bank*, *Mayo Collaborative Services v. Prometheus Laboratories*) blatantly overturning the protection of DNA and other genetic sequences from becoming patent eligible. To combat this, AMP met with various offices in both the House and Senate to push back on the PERA and relay the devastating consequences it would have on patient access and scientific innovation.

## **Capitol Hill Happenings**

AMP continues to foster existing partnerships on Capitol Hill. AMP Advocacy participated in over 45 congressional meetings in 2024 that focused on gene patent law, laboratory diagnostics legislation and regulation, AMP’s CLIA Modernization proposal and the Protecting Access to Medicare Act (PAMA)/Saving Access to Laboratory Services Act (SALSA). This year, AMP staff participated as a panelist in a Congressional briefing on gene patent legislation, the Patent Eligibility Restoration Act, 2023 (PERA), and co-led a CLIA modernization Congressional briefing and Hill Day, in collaboration with Bioreference labs and the Coalition for Innovative Lab Testing.

## **Patient Advocacy Group Engagement**

AMP has had several Patient Advocacy initiatives in 2024. In 2024, AMP released it’s first 90-second animation for patient education entitled “Inside a Molecular Laboratory”

The Patient Engagement working group also released a Screening vs Diagnostic Video Series which builds upon the Infographic series that serves to educate the public on the differences between screening and confirmatory diagnostic tests. These videos include Breast Cancer and Hepatitis C testing.

The Patient Engagement Subcommittee is currently working on the following projects:

- “What is Liquid Biopsy?” video
- Molecular in the Patient’s Pocket Card, “My Cancer Journey”

## **Collaborations**

AMP continues to participate in a variety of policy discussions with other professional societies, laboratory groups, such as the National Academies of Sciences, Engineering, and Medicine (NASEM) Roundtable on Genomics and Precision Health (AMP representative **Dr. Vicky Pratt**), Federation of American Societies for Experimental Biology (FASEB) (AMP representative **Dr. Emilia Calvaresi**), and the Personalized Medicine Coalition (PMC), Cancer Leadership Council, Coalition for Innovation Lab Testing, Laboratory Access and Benefits (LAB) Coalition.

## AMP Program Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Jonathan Nowak, PhD
Chair-Elect	Somak Roy, MD
Genetics Subdivision Representative	Honey Reddi, PhD
Genetics Subdivision Representative	Stuart A. Scott, PhD
Hematopathology Subdivision Representative	Craig Soderquist, MD
Hematopathology Subdivision Representative	Amir Behdad, MD
Infectious Diseases Subdivision Representative	Heba Mostafa, MD, PhD
Infectious Diseases Subdivision Representative	Ryan R. Relich, PhD
Informatics Subdivision Representative	Julie Hirschhorn, PhD
Informatics Subdivision Representative	Heather Blankenship, PhD
Solid Tumors Subdivision Representative	Deepika Sirohi, MD
Solid Tumors Subdivision Representative	Arivarasan Karunamurthy, MD
Technical Topics Representative	Tracy McMillen, MS
Technical Topics Representative	Tessara Baldi, BS
Member ( <i>Ex Officio</i> – President)	Maria E. Arcila, MD
Member ( <i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

### PURPOSE SUMMARY:

The Program Committee is responsible for overall planning and organization of the AMP Annual Meeting, including sessions and abstracts/posters. In addition, the Committee selects the winners of the Technologist Poster Awards.

### 2024 ACTIVITIES:

Planned and moderated the sessions for the 2024 Annual Meeting & from November 19-23, 2024, along with the recorded content that will be available in January 2025.

## AMP Publications Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Patricia Tsang, MD, MBA
<i>JMD</i> Editor-in-Chief	Ronald M. Przygodzki, MD
Member	Yogesh Chander, PhD
Member	Annacarolina Fabiana Lucia da Silva, MD
Member	Midhat S. Farooqi, MD, PhD
Member	Juehua Gao, MD, PhD
Junior Member	Patricia Hernandez, MD
Member	Arivarasan Karunamurthy, MBBS, MD
Member	Madhu M Ouseph, MD, PhD
Member	Thuy L. Phung, MD, PhD
Member	Daniel Sabath, MD, PhD
Member	Zheng Jin Tu, PhD
Member	Barbara A. Zehnbauer, PhD
<i>JMD</i> Managing Editor	Emily Essex
<i>JMD</i> Scientific Editor	Chhavi Chauhan, PhD
Member ( <i>Ex Officio</i> – President)	Maria E. Arcila, MD
Member ( <i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

**PURPOSE SUMMARY:** Members of the Publications Committee are appointed by the Board to serve up to six (6) two-year, renewable terms, and a junior member to serve a two-year term.

- The Publications Committee has certain responsibilities for AMP’s official journal, *The Journal of Molecular Diagnostics (JMD)*, which is co-owned by the American Society for Investigative Pathology (ASIP), including advisory to AMP’s Board and ASIP’s Council regarding *JMD* policy issues; scope statement; business success; publisher Request for Proposal and selection; selection of Editors and Editorial Board members; performance expectations for Editors.
- The Publications Committee does not oversee *JMD*’s production or editorial functions; however, it may request or receive information and make recommendations to the Editor-in-Chief and Managing Editor.
- The Committee reviews AMP member submissions of Case Reports for potential publication in *CAP Today*.
- The Committee holds a virtual meeting monthly, meets face-to-face before the annual meeting, and communicates electronically throughout the year.

### 2024 ACTIVITIES:

- Solicited and reviewed AMP Case Reports submissions for potential publication in *CAP Today*.
- Established a task force to create recommendations to improve the AMP Case Reports in *CAP Today* program.
- Established a task force to review Elsevier’s proposal regarding their contract with *JMD*.
- Recommends up to two *JMD* articles for the *AMPLifications* Newsletter on a monthly basis.
- Developed a potential topics and authors list for *JMD* review articles, guest editorials, spotlight pages, and Silver Anniversary Edition.
- Reviews and updates the AMP Wikipedia page, as needed.
- Assisted with revising previous *JMD* surveys to receive insight from readers, authors, and reviewers.

- List of AMP Case Report authors published in *CAP Today* since November 2023
  - *Potential von Hippel-Lindau syndrome in a patient with negative germline testing*
    - Corresponding Author
      - Yang Cao, PhD, FACMG, Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA
    - Additional Authors
      - Patricia V. Hernandez, MD
      - Andrea Stacy, MS
      - Meagan Corliss, MS
      - Kevin M. Bowling, PhD
  - *Acute Myeloid Leukemia with Hyperdiploidy*
    - Corresponding Author
      - Zeeshan Ansar, MBBS, FCPS, Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan
    - Additional Authors
      - Hareem Alam, MBBS, FCPS
      - Muhammad Shariq, MBBS, FCPS
      - Hasan Hayat
      - Asghar Nasir, PhD
      - Tariq Moatter, PhD
  - *The Use of Molecular Techniques to Solve a Challenging Case of Extra Nodal Marginal Zone Lymphoma*
    - Corresponding Author
      - Pritish Bhattacharyya, MD, Department of Pathology, Hackensack University Medical Center, Hackensack, NJ, USA
    - Additional Authors
      - Maciej Kabat, MD
      - Anja Jones, MD
      - Xiangyang Li, MS
      - Tatyana Feldman, MD
      - Xiao Yang, MD
      - Jennifer Zepf, DO
      - Kar Chow, MD
  - *Male or female? Integrated molecular and cytogenetic testing resolves discordant prenatal results*
    - Corresponding Author
      - Ting Wen, MD PhD, ARUP Laboratories / University of Utah, Department of Pathology, UT, USA
    - Additional Authors
      - Daniel Reich, PhD
      - Jian Zhao, PhD
      - Denise I. Quigley, PhD



- Rong Mao, MD
- Katie Rudd, PhD

### **Requests from the Publications Committee**

- We encourage AMP members to serve as a reviewer for the *Journal of Molecular Diagnostics*. Please [register an account](#) on the JMDI Editorial Manager platform and enter applicable expertise terms/keywords to your profile. AMP membership is not required.
- We encourage AMP members to submit Case Reports for potential publication in *CAP Today*. More information about the program and online submission portal is available on our [website](#).

## AMP Strategic Opportunities Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Jane Gibson, PhD
Board Member	Yasmine Akkari, PhD
Board Member	Panieh Terraf, PhD
Member	Estevan Kiernan, Masters
Member	Jordan Laser, MD
Member	Federico Monzon, MD
Member	Nirali Patel, MD
Member	Anthony Sireci, MD
President	Maria Arcila, MD
Chief Executive Officer	Laurie Menser, CAE

### PURPOSE SUMMARY:

The Strategic Opportunities Committee assesses the opportunities and challenges in the molecular pathology profession and other environments external to the organization that affect AMP interests.

### 2024 ACTIVITIES:

- Identified and assessed the opportunities and challenges in the molecular pathology profession and other environments that affect AMP interests, including:
  - external threats that could prevent AMP from attaining its goals
  - external opportunities that can help AMP attain its goals
  - organizations for potential relationships that can help AMP attain its goals
- Provided relevant recommendations to the Board of Directors

## AMP Training & Education Committee Annual Report, 2024

### COMMITTEE MEMBERS:

Chair	Marjorie David, MD
Genetics Subdivision Representative	Eli Williams, PhD
Genetics Subdivision Representative	Sara Akhavanfard, MD, PhD
Hematopathology Subdivision Representative	Joanna Conant, MD
Hematopathology Subdivision Representative	Kevin E. Fisher, MD, PhD
Infectious Diseases Subdivision Representative	Cecilia Thompson, PhD
Infectious Diseases Subdivision Representative	Rebecca Yee, PhD
Informatics Subdivision Representative	Jamal Benhamida, MD
Informatics Subdivision Representative	Eric W. Klee, PhD
Solid Tumors Subdivision Representative	Anna Matynia, MD
Solid Tumors Subdivision Representative	Brett Baskovich, MD
Junior Member	Kenneth Ofori, MBCHB
Junior Member	Alexander Neil, MD, PhD
Medical Technologist Member	Margaret Cameron, MS
Medical Technologist Member	Carlo Ledesma
Membership Affairs Committee Liaison	Yang Cao, PhD, FACMG
International Affairs Committee Liaison	Roberta Sitnik, PhD
Member ( <i>Ex Officio</i> – President)	Maria E. Arcila, MD
Member ( <i>Ex Officio</i> – Chief Executive Officer)	Laurie S. Menser, CAE

### PURPOSE SUMMARY:

The Training and Education (T&E) Committee is comprised of representatives from each of AMP's subdivisions: genetics, hematopathology, infectious diseases, informatics, and solid tumors as well as technologist representatives, junior members, and liaisons from the International Affairs and Membership Affairs Committees (IAC and MAC). It oversees important issues such as education and certification in molecular pathology and mentoring of trainees, as well as developing educational programs for different audiences.

### ***AMP 2024 Annual Meeting & Expo Activities:***

#### **2024 GetAMPed! Updates and Case Studies in Molecular Pathology:**

The T&E Committee planned and taught an in-person course for the AMP 2023 Annual Meeting & Expo on November 20<sup>th</sup>. This year, the course was taught twice as 3.5-hour long sessions focus on informatics and data processing, NGS, and standard molecular pathology techniques including applications for infectious disease testing. The course included four interactive case study break-out sessions which enabled participants to apply what they learned to cases in infectious diseases, solid tumors, hematopathology, and genetics.

#### **Early Bird Sessions at the Annual Meeting & Expo - Case Studies Presented by Trainees or Technologists:**

The T&E Committee hosted an opportunity for fellows, residents, postdocs, graduate students, or technologists to present an interesting and/or challenging case study for the AMP 2024 Annual Meeting and Expo. Trainee/technologist presenters in 2024 are listed below:

Case Studies in Genetics	Novel FANCD2 variant leading to somatic rescue in a patient with Fanconi anemia	Poorva Singh	University of Minnesota
	Incidental Discovery of a Sex Chromosome Disorder During Somatic Testing in a Phenotypically Male Lung Cancer Patient: A Multidisciplinary Dilemma	Michael Christensen	Hospital of the University of Pennsylvania
	Multimodal Approach for the Diagnosis of Placental Mesenchymal Dysplasia	Nakul Shankar	University of Colorado Anschutz Medical Campus
	DICER1 Syndrome with Embryonal Rhabdomyosarcoma and Fetal Lung Adenocarcinoma in a Young Female	Vandana Baloda	Memorial Sloan Kettering Cancer Center
Case Studies in Infectious Diseases	Molecular diagnosis of Bordetella: A Case of Confusion with B. bronchiseptica	Christopher Zarbock	Washington University School of Medicine
Case Studies in Hematopathology	Extramedullary NPM1+ acute myeloid leukemia transformation in the setting of “chronic phase” primary myelofibrosis in the bone marrow	Rebecca Ramesh	Penn Medicine
	Identifying the Signal in the Signal: Incidental Detection of B-Cell Lymphoma Related Variants in the Molecular Profiling of a Spindle Cell Sarcoma	Ting Zhao	Massachusetts General Hospital, Harvard Medical School
	Optical Genome Mapping complemented with DNA sequencing detects prognostic markers in a rare T-cell leukemia and refines the cytogenetics work-up	Lauren Wainman	Dartmouth-Hitchcock Medical Center
	Rare TBL1XR1-JAK2 fusion in a patient with pediatric T-cell acute lymphoblastic leukemia identified by Optical Genome Mapping.	Aravindh Nagarajan	Children's Mercy Hospital
	Acute myeloid leukemia with t(8;16)(p11;p13)/KAT6A::CREBBP identified by whole-genome sequencing	Patricia Hernandez	Washington University School of Medicine
	Unmasking the Unexpected: A Case of Silent PNH in a Young Woman	Sidra Zaheer	Columbia University Irving Medical Center
	A Blastoid Mystery: Low-Grade Origins, High-Grade Evolution?	Aaron Victor	Cedars-Sinai Medical Center
	Case Studies in Solid Tumors	Molecular Profiling is a Helpful Tool in Diagnosing MMNST	Rasha Alfattal
A Rare Case of Infant Type Hemispheric Glioma with Aggressive Course and Novel Targetable PRKAR2A::ALK fusion		Mine Yilmaz	Columbia University
EGFR Exon 20 Insertion Mutation as the Defining Genomic Alteration and Grade Determination in a Diffuse Thalamic Glioma		Chihoon Ahn	Baylor College of Medicine
Liquid biopsy guides diagnostic algorithm in a case with two metachronous primary tumors		Nisha Kanwar	Mayo Clinic
Genomic Analysis as a Precision Tool for Daily Diagnostic Challenges: First Case Report Showing Definitive Molecular Evidence for Distant Drop Metastasis of Colonic Adenocarcinoma		Jiejun Wu	University of California, San Francisco
Navigating the challenges of identifying the causative CIC::DUX4 gene fusion using whole transcriptome RNA sequencing		Elan Hahn	University of Pittsburgh Medical Centre
Distinct Atypical Meningiomas Hiding in Plain Sight, Out SMARCB1 by SMARCB1		Joshua Klonoski	University of Colorado
Comprehensive Genomic Testing as a Tool for Robust Characterization of Putative Splice Site Variants: An Illustrative Case		Pari Jafari	University of Chicago Medicine

- The Molecular Genetic Pathology Fellowship Program Directors (MGP PD) Council**  
 The MGP Program Directors (MGP PD) Council consists of Noah Brown (Chair), Bijal Parikh (Chair-Elect), and Mark Ewalt (Past-Chair). Anna Matynia acts as the T&E committee representative to this group. The MGP PD Council facilitates the discussions of the MGP Program Directors Working Group and responds to the ABP and ACGME on matters related to MGP Fellowship programs. This year, they successfully gathered enough support (32) from the 40+ programs to proceed with the Match recruitment for 2026-2027. The MGP program directors will meet at the AMP 2024 Annual Meeting & Expo, to discuss the match process.
- The Education Community of Practice (EdCoP) Group**  
 The AMP Education Community of Practice Group is lead by Thomas Lee with working group members Yang Cao, Lulu Sun, and Erica Vormittag-Nocito. In 2024, the working group began the task of mapping educational resources to core competencies identified in molecular pathology curriculum manuscripts. The EdCoP group also hosted a webinar called “Teach the teacher in molecular diagnostics” and held a meeting at the AMP Annual Meeting and Expo showcasing their annotated list of teaching resources linked to common teaching curricula.
- Innovation Stages**  
 The T&E Committee will be hosting two Innovation Stages. One of the mentorship program and another on T&E initiatives.
- Trainee Networking Luncheon**  
 Trainees will be invited to learn about how to maximize use of publicly available datasets, machine learning, and online knowledgebases in routine molecular pathology practice, translational research, and innovation over lunch. There will also be a book drawing.
- Technologist Networking Luncheon**  
 The luncheon will be a social opportunity to share working and learning experiences with others in the field of laboratory technology.

### **Other 2024 T&E Activities**

#### **2024 Live Webinars and Recorded Online Content (ROCs):**

Date	Title	Speaker/T&E Moderator	NOTES (Registrants/Attendees)
<b>Major Initiative: <a href="#">Breast Cancer Molecular Testing: Catching Up to Increased Complexity</a></b>			
February 28	Somatic NGS Tumor Testing in Breast Cancer	Deborah Dillon	781/280
April 2	Modifiable Genetic & Non Genetic Risk Factors for Breast Cancer	Olufunmilayo I. Olopade	351/125
<b>Major Initiative: <a href="#">Emerging and Evolving Biomarkers: Recent Findings, Laboratory Considerations, and Clinical Implications</a></b>			
March 14	Oncogenic RET Fusions: Biology, Testing, and Treatment	Soo-Ryum Yang	184/97
June 20	TP53 Mutations in Myeloid Neoplasms: From Clonal Hematopoiesis to Acute Leukemia	Robert Hasserjian	283/108
October 31	Molecular Classification and Predictive Biomarkers in Endometrial Carcinoma	Brooke Howitt	TBD

Date	Title	Speaker/T&E Moderator	NOTES (Registrants/Attendees)
<b>Webinar Series: Horizons</b>			
April 23	Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors	Alexander Gusev	182/73
July 18	Introduction to FHIR: Applications in Pathology	Alexander Goel	127/45
October 24	Influenza Outbreaks and Understanding the Current H5N1 Situation	Marty Soehnlén, Sanchita Das, Richard Webby	TBD
<b>Webinar Series: Horizons; Clinical Practice Webinars</b>			
March 21	Exploring the Utility of Multiplex Infectious Disease Panel Testing for Diagnosis of Infection in Different Body Sites	Esther Babady	516/255
April 11	Recommendations for Cell-Free DNA Assay Validations	Christina Lockwood	1012/468
May 21	Slice Testing - Considerations from Ordering to Reporting	Rong Mao	505/229
September 10	Recommendations for Tumor Mutational Burden Assay Validation and Reporting	Larissa Furtado	682/304
October 15	DPYD Genotyping Recommendations	Reynolds Ly	TBD
<b>Webinar Series: Trainee and Early Career Series</b>			
May 1	Starting a New Faculty Position	Marco Leung; Jennifer Yoest; Margaret Black; Lauren Choate	199/97
July 24	Live Panel Discussion: An Introduction to Careers in Industry	Douglas A. Mata, MD, MPH, Nirali M. Patel, MD, Angela M. Verdoni, PhD, DABMGG	281/93
September 4	Excelling in the LGG Board Exam: Strategies, Resources, and Insights from Recent Graduates	Alaa Koleilat, Claire Hou, Laura Sack	230/144
<b>Webinar Series: EdCoP Series</b>			
May 29	Teach the teacher in molecular diagnostics	Peter Hu	380/161

- **[Online Education - AMPED™:](#)**

The T&E Committee and staff have designed and developed educational materials for populating [educate.amp.org](https://educate.amp.org). The LMS has attracted over 4,300 active users in 2023 (January 2023-December 31, 2023) where 59% of the users were non AMP members and over 30% from outside of the US.

- **[Course Bundles/AMP Certificate Programs:](#)** Courses are live programs that were recorded and translated to a self-paced online course. Certificate programs are self-paced on-demand content designed to provide a deep dive on specific areas of interest. New courses and certificate programs launched in 2024 include:
  - [Breast Cancer Virtual Education Series](#)
  - [Testing for Homologous Recombination Deficiency in Cancer: Diagnostic Strategies and Clinical Perspectives](#)

- **AMP Flashcards:** We currently have 5 flashcards sets available on AMPED™ The cards can also be used as study aids for ASCP certification exams. In addition, there are four more sets available: 1) [multiple myeloma](#), 2) [colorectal cancer](#) 3) [acute myeloid leukemia](#), 4) [Technologist in Molecular Biology: Laboratory Operations](#), and 5) [Technologist in Molecular Biology: Molecular Techniques](#)
- **FISE Question Bank:** This is the seventh year of a continuing collaboration with the MGP-PD Council to provide fellows with a Fellowship In-Service Examination (FISE) at the beginning and at the end of their fellowship year. Additional FISE exam questions were written by MGP faculty and reviewed by the T&E. The bank currently consists of >500 questions and learners are presented with 45 randomly selected questions for their examination. AMP staff provides non-attributed results to participating institutions at the beginning of the fellowship year (in October) and at the end of the year (in May/June).
- **Molecular in a Minute:** Since its initiation in 2021, the T&E Committee completed 15 microlearning modules called Molecular in a Minute. There are plans to add an additional 3 and to increase its visibility by using AMP's social media accounts.
- **Molecular-in-My-Pocket™ cards:** The T&E Committee continued expanding the Molecular-in-My-Pocket™ reference card collection. One new card ([Neuropathology](#)) was created. The T&E has also made substantial edits to many of the cards. Cards are reviewed annually by the Assessment Content Editing Group (under the purview of the T&E Committee) for accuracy and for any required updates. There have been more than 2,500 user visits to the MIMP card homepage in the past 6 months.
- **Portuguese Translations:** Two on demand videos now include Portuguese captioning and transcription to increase access to non-English speaking molecular professionals. The two webinars that have been translated are: *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists* and *Preanalytical Considerations* (excerpted from the GetAMPed! Updates in Case Studies in Molecular Pathology course).

- **Molecular Genetic Pathology Review Course:**

In May 2023, the Molecular Genetic Pathology Review course was held as a 4-day virtual-live course. With 15 molecular genetic pathology expert faculty speaking on topics ranging from molecular technologies, test validations and statistics, molecular oncology, infectious diseases and more, the course was designed to assist attendees in preparing for the MGP subspecialty certification exam as well as other exams in molecular pathology. This course was recorded and posted as a self-paced on demand course. From June 2023 – October 2024, a total of 51 learners enrolled in the MGP online course.

***Education Partnerships/Collaborations, Co-Sponsorships, Companion Meetings***

- **United States and Canadian Academy of Pathology (USCAP) March 2024 – Baltimore, MD**

***The AMP 2024 Companion Society Symposium,***

“Emerging Genomic Technologies for Diagnostics in Pathology”, was co-moderated by Rashmi Kanagal-Shamanna, MD and Adam S. Fisch, MD, PhD.

Speakers were:

Claudia Haferlach

Adam C. Smith, PhD

Alena Skalova, MD, PhD

Daniel L. Faden, MD

***Short Course,***

“A Primer in Precision Pathology: Digital and Computational Pathology, Omics and Spatial Profiling”,  
was co-moderated by George Netto, MD and Karen Kaul, MD

Speakers were:

Mathew Hanna, MD	Jonathan Nowak, MD, PhD
Stuart J. Schnitt, MD	David Rimm, MD, PhD
Sinchita Roy Chowdhuri, MD	Brooke Howitt, MD
Zubair Baloch, MD, PhD	Craig M. Horbinski, MD
Andrew L. Folpe, MD	Alexis Carter, MD

- **American Association of Neuropathologists – Virtual course**

“Molecular Neuropathology Course” (August 2024 – May 2025). Partnership enables AMP members to attend the course at a discounted rate.

- **National Society of Genetic Counselors –Short course**

“Advanced Genomic Technologies: Coming Soon to a Clinic Near You” (September 2024). AMP representatives included Honey Reddi, PhD and Ying Zou, PhD

- **Cor2Ed – online education**

**Pre-analytical Phase Challenges and Biomarker Testing** – Released 1/2024 ~present. Seven educational activities focused on preanalytical considerations in multiple cancer types.



## AMP Subdivision Leadership Annual Report, 2024

### SUBDIVISION LEADERSHIP

	Genetics	Hematopathology	Infectious Diseases	Informatics	Solid Tumors
<b>Chair</b>	Matt Lebo	Rena Xian	Kirsten St. George	Annette Leon	Anthony Snow
<b>Clinical Practice Committee</b>	Jennifer Laffin	Susan Harley	Meghan Starolis	Weiwei Zhang	Lauren Ritterhouse
	Ann Moyer	Pawel Mroz	Erin Graf	Andrea Sboner	Katherine Geiersbach
<b>Economic Affairs Committee</b>	Victoria Pratt	Patricia Tsang	Joseph Yao	Jeffrey Gagan	Susan Hsiao
<b>Nominating Committee</b>	Jane Houldsworth	Valentina Nardi	Morgan Pence	Jing Xu	Jaclyn Hechtman
	Tina Hambuch Hawks	Mark Ewalt	Ana Maria Cárdenas	Ahmet Zehir	Nikoletta Sidiropoulos
<b>Professional Relations Committee</b>	Xiaoli Du	Betty Chung	Heather Blankenship	Jason Rosenbaum	Bryan Iorgulescu
<b>Program Committee</b>	Stuart Scott	Amir Behdad	Ryan Relich	Heather Blankenship	Arivarasan Karunamurthy
	Honey Reddi	Craig Soderquist	Heba Mostafa	Julie Hirschhorn	Deepika Sirohi
<b>Training &amp; Education Committee</b>	Sara Akhavanfard	Kevin Fisher	Rebecca Yee	Eric Klee	Brett Baskovich
	Eli Williams	Joanna Conant	Cecilia Thompson	Jamal Benhamida	Anna Matynia

### PURPOSE SUMMARY:

The Subdivision Leadership (SL) consists of a Chair, representatives to the Clinical Practice, Economic Affairs, Nominating, Program, Professional Relations, Training & Education Committees, and *ad hoc* representatives to the Subdivision Leadership groups from the Professional Relations and Economic Affairs Committees. Subdivision Chairs are responsible for the successful operation and development of the subdivision that they lead.

Each Subdivision Leadership group meets quarterly and functions in an AMP advisory panel of discipline-specific subject matter experts convened to address issues of importance to their Subdivision. They carry out their subdivision leadership responsibilities by:

- Identifying and ascertaining the needs of the Subdivision membership and of the discipline itself
- Providing feedback regarding projects to the Clinical Practice Committee, Training and Education Committee, or other relevant committees
- Providing input and suggestions regarding content for the Annual Meeting and other educational events
- Assisting to identify and recommend future AMP volunteers and leaders
- Resource for advocacy-related initiatives

## 2024 ACTIVITIES:

All Subdivision Leadership groups contribute to biannual Subdivision Spotlight email digests that highlight AMP activities and *JMD* articles related to Subdivision member's interests. Acted on AMP's Board of Committee's request from the Early Career Committee to solicit volunteer applications for a junior member for each SL.

**Genetics** - Served as AMP's internal advisory board for genetics to develop initiatives related to clinical practice, advocacy, and education. Addressed current issues and topics related to genetics, including variant interpretation and classification, next-generation sequencing, pharmacogenomics, whole genome and exome sequencing standards, forensics, and diversity in genomic databases. Established group of SMEs to write a guest editorial for *JMD*'s Silver Editions, addressing the current and future outlook of genetics. Participated and contributed to projects related to the different AMP Committees.

**Hematopathology** - Served as AMP's internal advisory board for hematopathology to develop initiatives related to clinical practice, advocacy, and education. Addressed current issues and topics in molecular hematopathology, including advances in translational research related to myelomas, MRD monitoring in hematologic malignancies, next-generation sequencing, and immunology. Established group of SMEs to write a guest editorial for *JMD*'s Silver Editions, addressing the current and future outlook of hematopathology. Participated and contributed to projects related to the different AMP Committees. Curated and provided a "Must Reads" list of hematopathology-relevant literature biannually for the AMP Hematopathology Subdivision Spotlight email digests.

**Infectious Diseases** - Served as AMP's internal advisory board for infectious diseases to develop initiatives related to clinical practice, advocacy, and education. Addressed current issues and topics related to the clinical molecular diagnostics laboratory, including next generation sequencing, artificial intelligence and machine learning, antimicrobial resistance, SARS-CoV-2, Mpox, and microbiome. Created a task force to maintain AMP websites related to SARS-CoV-2, Mpox, H5N1 Bird Flu, and Measles resources. Provided feedback to a *JMD* Associate Editor related to increasing and improving infectious disease related articles and highlighting AMP ID Subdivision activities in the journal. Established group of SMEs to write a guest editorial for *JMD*'s Silver Editions, addressing the current and future outlook of infectious diseases. Participated and contributed to projects related to the different AMP Committees.

**Informatics** - Served as AMP's internal advisory board for informatics to develop initiatives related to clinical practice, advocacy, and education. Addressed current issues and topics related to development of bioinformatics pipelines for clinical next-generation sequencing, informatics tools in metagenomics, electronic health record (EHR) interoperability for clinical genomics data, and body of knowledge (BoK) for Clinical Bioinformaticist. Assisted the Clinical Practice Committee (CPC) with topics involving artificial intelligence and machine learning. Established group of SMEs to write a guest editorial for *JMD*'s Silver Editions, addressing the current and future outlook of informatics. Participated and contributed to projects related to the different AMP Committees.

**Solid Tumors** - Served as AMP's internal advisory board for solid tumors to develop initiatives related to clinical practice, advocacy, and education. Addressed various current issues and topics related to clinical applications of circulating tumor cells, gene fusions, homologous recombination deficiency (HRD), liquid biopsies, tumor mutational burden, and other factors related to clinical practice of cancer. Discussed oncology-related clinical practice areas in need of additional expert guidance. Established group of SMEs to write a guest editorial for *JMD*'s Silver Editions, addressing the current and future outlook of solid tumors. Participated and contributed to projects related to the different AMP Committees.

### **Requests from the Subdivision Leadership**

- We encourage all AMP members to alert their Subdivision Chair or Representatives to current or emerging specific needs that AMP should consider and address.
- We encourage AMP members to actively contribute to requests for information from their respective Subdivision Leadership.
- We encourage AMP members to serve as a reviewer for the *Journal of Molecular Diagnostics*. Please [register an account](#) on the JMDI Editorial Manager platform and enter applicable expertise terms/keywords to your profile. AMP membership is not required.